Literature DB >> 22890192

Genetic diversity and clonal evolution of carbapenem-resistant Acinetobacter baumannii isolates from Portugal and the dissemination of ST118.

V Manageiro1, D Jones-Dias, E Ferreira, D Louro, M Caniça.   

Abstract

In this study, 116 multidrug-resistant Acinetobacter baumannii (MDR-Ab) isolates recovered in various regions of Portugal were studied. All isolates were non-susceptible to tigecycline; one isolate was also non-susceptible to colistin, making it a step closer to pandrug resistance. Among 72 isolates tested by PFGE, 98.6% carried bla(OXA-66), 1.4% bla(OXA-104), 77.8% bla(OXA-23), 23.6% bla(OXA-24), 18.1% bla(TEM-1) and 1.4% bla(CTX-M-15-like) genes. No OXA-58 or metallo-β-lactamase-encoding genes were detected. ISAba1 was found in 58/72 isolates (80.6%). Among these, ISAba1 was found upstream of bla(OXA-51-like) in 54 isolates. All but two of these isolates also carried ISAba1-bla(OXA-23), highlighting the coexistence of ISAba1-bla(OXA-51-like) and ISAba1-bla(OXA-23) genetic platforms, emphasising the importance of mobile genetic elements in the dissemination of carbapenem-hydrolysing class D β-lactamase genes. Tn2006-like and Tn2008-like, found within ST92 and ST118, may reflect either multiple genetic structures in the origin of bla(OXA-23) acquisition or interclonal complex evolution. These results indicate that there may exist different genetic origins for carbapenem resistance among MDR-Ab isolates. Six PFGE profiles were associated with three major sequence types, with ST118 (OXA-23- or OXA-24-producer) being widely disseminated since 2009. ST98 (described so far as endemic in Portugal) and ST92 (which co-existed with ST98 before 2009) appeared to have been gradually replaced by ST118. The new ST188 (OXA-104-producer) was detected for the first time in this country. Identification of an extensively drug-resistant ST118 and carbapenem-resistant ST92, ST98 and ST118 isolates, both in community and healthcare facilities, demonstrates the menace of A. baumannii-associated infections.
Copyright © 2012 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890192     DOI: 10.1016/j.ijantimicag.2012.06.013

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  5 in total

1.  First report of OXA-23-mediated carbapenem resistance in sequence type 2 multidrug-resistant Acinetobacter baumannii associated with urinary tract infection in a cat.

Authors:  Constança Pomba; Andrea Endimiani; Alexandra Rossano; Dolores Saial; Natacha Couto; Vincent Perreten
Journal:  Antimicrob Agents Chemother       Date:  2013-12-02       Impact factor: 5.191

2.  Globally expanding carbapenemase finally appears in Spain: nosocomial outbreak of acinetobacter baumannii producing plasmid-encoded OXA-23 in Barcelona, Spain.

Authors:  Noraida Mosqueda; Paula Espinal; Clara Cosgaya; Sergio Viota; Virginia Plasensia; Francisco Alvarez-Lerma; Milagro Montero; Julià Gómez; Juan Pablo Horcajada; Jordi Vila; Ignasi Roca
Journal:  Antimicrob Agents Chemother       Date:  2013-07-22       Impact factor: 5.191

3.  Genotyping of carbapenem resistant Acinetobacter baumannii isolated from tracheal tube discharge of hospitalized patients in intensive care units, Ahvaz, Iran.

Authors:  Saeed Shoja; Mojtaba Moosavian; Amir Peymani; Mohammad Amin Tabatabaiefar; Soodabeh Rostami; Nasim Ebrahimi
Journal:  Iran J Microbiol       Date:  2013-12

4.  blaOXA-23-like and blaTEM rather than blaOXA-51-like contributed to a high level of carbapenem resistance in Acinetobacter baumannii strains from a teaching hospital in Xi'an, China.

Authors:  Lei Han; Jine Lei; Jiru Xu; Shaoshan Han
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

5.  Characterization of Oxacillinase and Metallo-β-Lactamas Genes and Molecular Typing of Clinical Isolates of Acinetobacter baumannii in Ahvaz, South-West of Iran.

Authors:  Saeed Shoja; Mojtaba Moosavian; Soodabeh Rostami; Fariba Abbasi; Mohammad Amin Tabatabaiefar; Amir Peymani
Journal:  Jundishapur J Microbiol       Date:  2016-02-13       Impact factor: 0.747

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.